Drug Database
EP

eprosartan mesylate + HCTZ (Teveten Combi / Teveten HCT / Teveten Plus)

✓ Approved

AbbVie, Inc. · AGTR1 · Small Molecule

What is eprosartan mesylate + HCTZ?

eprosartan mesylate + HCTZ is a small molecule developed by AbbVie, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesTeveten Combi, Teveten HCT, Teveten Plus
CompanyAbbVie, Inc.
Drug ClassSmall Molecule
Molecular TargetAGTR1, SLC12A3
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, AbbVie, Inc.

Mechanism of Action

Molecular Targets

eprosartan mesylate + HCTZ acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

eprosartan mesylate + HCTZ is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedEnvironmental toxicology and pharmacology2026-05-22

Risk of skin cancer from hydrochlorothiazide and other diuretics across races: a global cohort study.

Lee Chaw-Ning CN, Shao Shih-Chieh SC, Yang Chao-Chun CC, Hung Jia-Horung JH et al.

Hydrochlorothiazide (HCTZ) has been linked to increased skin cancer risk. However, comparative evidence across racial groups remains limited. Using TriNetX, a global database, we evaluated the association between thiazide diuretic use and skin cancer risk across whites and other races within a single analytic platform, including both HCTZ and non-HCTZ thiazides. To determine if the skin cancer risk associated with thiazide diuretics varies by racial group. Using the TriNetX platform, we analyzed adults with newly treated hypertension, applying propensity score matching for baseline covariates, and calculated adjusted hazard ratios (aHRs) for skin cancers. Comparing to non-diuretic antihypertensive drug (NDAH) use, HCTZ increased the risk of keratinocyte carcinomas (KC) (aHR 1.40), squamous cell carcinoma (aHR 1.75), basal cell carcinoma (aHR 1.46), and malignant melanoma (aHR 1.37) only in the White population. No increased risk was found in the Asian, Hispanic, or Black populations. Chlorthalidone showed a similar pattern for KC, with increased event rates only in the White population. HCTZ is associated with an increased risk of skin cancers only among whites, while similar associations were not observed in other races. These findings may be considered when prescribing thiazide diuretics in this population.

PMID 42167389
Read full article →
PubMedThrombosis journal2026-05-21

A scoping review of factors affecting activated clotting time measurement results.

Itagaki Yuki Y, Hayakawa Mineji M, Okamoto Kaori K, Yashima Nozomi N et al.

Activated clotting time (ACT), a widely used point-of-care test, monitors anticoagulation in clinical settings. Despite ACT technology advancements, some uncertainties remain regarding the factors influencing ACT measurements and inter-device variability. Although ACT is widely used for anticoagulation monitoring in clinical practice, the factors affecting ACT values are not fully understood, complicating their interpretation. This scoping review aims to address these challenges by examining the factors affecting ACT measurements, highlighting gaps in current knowledge. A systematic search was conducted in MEDLINE (PubMed), including animal studies, clinical trials, observational studies, in vitro experiments, and systematic reviews. Article selection involved a two-step process: initial title and abstract screening followed by a full-text review, this was performed by three independent reviewers. Data from the included studies were charted and extracted, collecting information on factors influencing ACT measurements. A total of 1908 records were identified, with 74 studies included after screening. Key factors influencing ACT measurements included platelet count, platelet inhibitors, and hematocrit levels. Direct thrombin inhibitors, low-molecular-weight heparin, and direct oral anticoagulants prolonged ACT with characteristics different from heparin. Aprotinin and nafamostat mesylate interacted with coagulation activators during ACT measurements affecting results. Significant differences in ACT measurements were observed between devices. This scoping review comprehensively analyzed factors influencing ACT and emphasized ACT measurement variability across devices. Despite its widespread use as a point-of-care test for anticoagulation monitoring, ACT's limitations and device discrepancies highlight the need for cautious interpretation in clinical settings. Not applicable.

PMID 42163255
Read full article →
PubMedInvestigative ophthalmology & visual science2026-05-20

Activation of PPARγ Attenuates Age-Related Lacrimal Gland Dysfunction by Alleviating Endoplasmic Reticulum Stress-Mediated Ferroptosis.

Zhao Han H, Xu Yiming Y, Feng Peiwen P, Wang Xinyue X et al.

The potential mechanism underlying age-related lacrimal gland alterations remains unclear. Herein, we aimed to investigate the regulatory role of endoplasmic reticulum stress (ERS) and ferroptosis in the lacrimal glands of aging male C57BL/6J mice. Two- and 12-month-old male C57BL/6J mice were used in this study. The mice received an ERS inducer (tunicamycin), ERS inhibitor (4-phenylbutyric acid), a protein kinase R-like endoplasmic reticulum-resident kinase (PERK) inhibitor (GSK2606414), the ferroptosis inhibitors ferrostatin-1 (Fer-1), and deferoxamine mesylate (DFOM), or a peroxisome proliferator-activated receptor γ (PPARγ) agonist (rosiglitazone) or antagonist (GW9662). Histological structure, interstitial fibrosis, extraorbital lipid-droplet accumulation, and tear secretion in the lacrimal gland were examined. ERS biomarkers and the PERK pathway were upregulated in the aged lacrimal gland tissues. Concomitantly, ferroptosis levels were significantly increased in the lacrimal gland of 12-month-old mice; this finding was characterized by increased lipid peroxidation and oxidative stress and diminished levels of glutathione peroxidase 4, which was regulated by PERK. Furthermore, treatment with the PPARγ agonist rosiglitazone restored tear secretion and reduced PERK-mediated ERS and ferroptosis levels by increasing PPARγ levels in the aged lacrimal gland and alleviating lipid accumulation by enhancing fatty acid oxidation activity, thereby attenuating lipid metabolic disorders within the lacrimal gland of aged mice. However, these effects were reversed by the PPARγ antagonist GW9662. Our findings demonstrate that rosiglitazone alleviates age-related lacrimal dysfunction in mice through the PPARγ pathway. Our results offer a novel molecular target and therapeutic approach against age-related lacrimal gland disorders.

PMID 42159442
Read full article →
PubMedArtificial organs2026-05-20

Anticoagulation Strategies in Adults Undergoing Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.

Scharner Vincenz V, Lenz Karoline K, Herkner Harald H, Buchtele Nina N et al.

Extracorporeal membrane oxygenation (ECMO) is a life-saving intervention for patients with severe cardiac or respiratory failure, but it is associated with a high risk of thrombotic and bleeding complications. Unfractionated heparin (UFH) remains the most frequently used anticoagulant, largely due to historical practice and longstanding clinical familiarity, despite the absence of robust evidence from randomized controlled trials. Alternative strategies-including direct thrombin inhibitors (DTIs), low-molecular-weight heparins (LMWHs), nafamostat mesylate (NM), and no anticoagulation-are increasingly being explored. However, a comprehensive and contemporary comparison of these approaches has been lacking. We conducted a comprehensive search of PubMed/MEDLINE, EMBASE, and CENTRAL through March 2025, supplemented by manual searches of reference lists. We included randomized controlled trials and observational studies including patients 16 years or older receiving ECMO for ≥ 24 h that compared any anticoagulation strategy with another or with no anticoagulation. The primary outcome was thromboembolic events; secondary outcomes included bleeding and mortality. Risk of bias was assessed using validated tools. Meta-analyses were performed using a multivariable random-effects model, with prespecified subgroup analyses by ECMO modality (venoarterial [VA], venovenous [VV], or mixed) and subsequent sensitivity analyses. Twenty-one observational studies involving 2 775 adult ECMO patients were included, with UFH serving as the comparator in all studies. DTIs showed reduced thromboembolism (OR 0.73; 95% CI: 0.53-0.99) and were associated with significantly lower bleeding (OR 0.51; 95% CI: 0.39-0.67) and mortality (OR 0.70; 95% CI: 0.52-0.94), confirmed in a sensitivity analysis. LMWH was associated with significantly reduced odds of thromboembolic events (OR 0.26; 95% CI: 0.13-0.55), as well as showing a favorable bleeding profile (OR 0.46; 95% CI: 0.25-0.87), yet no significant difference in mortality (OR 0.80; 95% CI: 0.30-2.14). While no anticoagulation reduced the odds for bleeding (OR 0.17; 95% CI: 0.07-0.38) and NM showed no significant differences, both had wide confidence intervals, limiting interpretation. Heterogeneity for LMWH was low for efficacy and bleeding, yet substantial for mortality; for DTI, low to moderate; for no anticoagulation, low; and for NM, substantial to high on all comparisons. In this systematic review and meta-analysis, DTIs and LMWH appear to be effective and safe alternatives to UFH in adult ECMO, with consistent reductions in thromboembolic and bleeding events and a survival benefit observed for DTIs. These findings support reconsideration of UFH as the default anticoagulant and favor a more prominent role for alternative strategies in clinical practice. PROSPERO CRD42022363588.

PMID 42157673
Read full article →
PubMedbioRxiv : the preprint server for biology2026-05-18

Imatinib Reduces Right Ventricular Systolic Pressure Independent of Arterial or Venous Remodeling in an Inflammatory Murine Model of Pulmonary Hypertension.

McGlynn Madeleine M, Steffes Lea C LC, Shah Anvi A, Morales Joceline J et al.

Pulmonary arterial hypertension is a progressive, fatal disease driven by pathologic vascular remodeling including arterial medial hypertrophy, occlusive neointimal lesion formation, and venous muscularization. Current vasodilatory therapies improve hemodynamics but do not reverse established remodeling. Imatinib mesylate, a tyrosine kinase inhibitor targeting the PDGF-PDGFR signaling axis, has been proposed as an anti-remodeling therapy for pulmonary arterial hypertension and has demonstrated hemodynamic benefit in both preclinical models and clinical trials. However, prior preclinical models lack the neointimal lesions characteristic of human disease, effects on venous remodeling have not been examined, and direct histologic assessment in human trials is precluded by the invasiveness of serial lung biopsy. Here, leveraging the house dust mite mouse model of pulmonary hypertension, which recapitulates medial thickening, neointimal lesion formation, and venous muscularization, we rigorously evaluate the anti-remodeling and hemodynamic effects of imatinib during two defined remodeling stages: neointimal lesion growth and neointimal lesion maintenance. Imatinib treatment significantly reduced right ventricular systolic pressure at both stages. Despite this hemodynamic improvement, quantitative vessel-level analysis of over 1,700 arteries and 1,200 veins revealed no significant effect of imatinib on arterial medial thickness, neointimal lesion growth, neointimal lesion maintenance, or venous muscularization across any vessel size class. These findings dissociate imatinib's hemodynamic benefit from structural vascular remodeling and suggest that imatinib functions primarily as a pulmonary vasodilator rather than an anti-remodeling agent.

PMID 42146337
Read full article →
PubMedJournal of pharmaceutical and biomedical analysis2026-05-14

Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate.

Wang Yabo Y, Wu Zhengwei Z, Han Zhangjian Z, Li Zhuang Z et al.

As an oral small-molecule drug that selectively inhibits ROCK2, Belm exhibits unique advantages in the treatment of hormone-dependent/refractory cGVHD. However, impurity control and stability during the production of its API remain key challenges. This study conducted a systematic investigation into Belm's synthetic process, impurity analysis, toxicity evaluation, and quality control. First, the synthetic route was optimized to avoid the environmental hazards and low-yield issues of traditional routes. Nine relate impurities (including 5 new impurities: Imp-B, Imp-D, Imp-E, Imp-F and Imp-I) were successfully synthesized. An HPLC-based method for the separation and detection of Belm and its impurities was established, and method validation, Confirmed its applicability for API quality control. Impurity structures were elucidated by MS and NMR, and forced degradation studies (under acidic, basic, oxidative, thermal and photolysis conditions) were performed to reveal Belm's degradation behavior. Its mesylate form shows good stability under acidic and thermal conditions but is prone to forming new impurities (Imp-D1, Imp-D3 and Imp-D4) under basic, oxidative, and photolysis conditions. Toxicity prediction of impurities using ProTox-II and ADMETlab 3.0 indicated that Imp-D possesses significant immunotoxicity. Further network pharmacology analysis and molecular docking clarified the potential immunotoxicity mechanism of Imp-D. This study provides critical data support for the optimization of Belm's production process, formulation of impurity control strategies, and guarantee of stability. It also lays a foundation for its drug registration applications and full-life-cycle quality management.

PMID 42127555
Read full article →

+9447 more articles available with a free account

Sign up free to view all articles →

Ask about eprosartan mesylate + HCTZ